Status:
RECRUITING
Accelerated Biological Aging is Associated With Increased Risk of T2DM in the MASLD Population
Lead Sponsor:
Ningbo No. 1 Hospital
Conditions:
Type 2 Diabetes Mellitus (T2DM)
Metabolic Dysfunction-Associated Steatotic Liver Disease
Eligibility:
All Genders
20-90 years
Brief Summary
The association between biological aging and type 2 diabetes mellitus (T2DM) incidence in individuals with and without metabolic dysfunction-associated steatotic liver disease (MASLD) remains unclear....
Eligibility Criteria
Inclusion
- Abdominal ultrasound data available in annual health check-up records
- At least one of the following five metabolic indicators recorded annually:
- (1) Body mass index (BMI) or waist circumference (2) Blood pressure (3) Serum triglycerides (4) High-density lipoprotein cholesterol (HDL-C) (5) Fasting plasma glucose or glycated hemoglobin (HbA1c)
Exclusion
- Age \<20 or \>90 years
- Other causes of hepatic steatosis (e.g., alcoholic liver disease or hepatitis B infection)
- Type 2 diabetes mellitus at baseline
- Missing baseline data for any of the following variables: systolic blood pressure, albumin, alkaline phosphatase, blood urea nitrogen, creatinine, glycated hemoglobin (HbA1c), total cholesterol, lymphocyte percentage, white blood cell count, mean corpuscular volume, uric acid, fasting plasma glucose, and red cell distribution width (RDW)
Key Trial Info
Start Date :
April 1 2025
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 31 2025
Estimated Enrollment :
2720 Patients enrolled
Trial Details
Trial ID
NCT06984510
Start Date
April 1 2025
End Date
December 31 2025
Last Update
June 4 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
the First Affiliated Hospital of Ningbo University Ningbo, Zhejiang, China, 315000
Ningbo, Zhejiang, China, 315000